Broker Stock Recommendations for November 11, 2025: Buy or Sell Insights

Citigroup has significantly downgraded its rating for Trent, slashing the target price from Rs 7,150 to Rs 4,350. This decision comes amid concerns over weak consumption trends and rising competition, which analysts believe will further moderate Trent’s growth. In contrast, Stock Morgan Stanley maintains an optimistic outlook for Nykaa, projecting a target price of Rs 271, bolstered by strong performance in its beauty and fashion segments. Meanwhile, Goldman Sachs has issued a neutral rating for Divis Laboratories, while Jefferies has a buy rating for Torrent Pharma, reflecting varied sentiments across different sectors.

Trent’s Downgrade and Future Outlook

Citigroup’s downgrade of Trent to a “sell” rating has raised eyebrows in the investment community. Analysts attribute this decision to a combination of factors, including a persistent decline in overall consumption and the challenges posed by increasing competition. The brokerage has also revised its revenue estimates and earnings before interest, taxes, depreciation, and amortization (EBITDA) forecasts for the fiscal years 2026 to 2028. With the target price now set at Rs 4,350, down from Rs 7,150, investors are left questioning the company’s growth trajectory. The analysts predict that Trent’s growth rate will continue to slow, impacted by market cannibalization and the expansion of new stores.

Nykaa’s Strong Performance Amidst Market Challenges

In a contrasting report, Morgan Stanley has given Nykaa an “overweight” rating, setting a target price of Rs 271. The brokerage highlights the company’s robust performance in the beauty sector, which has shown consistent momentum. Additionally, Nykaa’s fashion business has experienced a notable improvement in gross merchandise value (GMV) growth. Analysts noted that the narrowing of EBITDA losses in the fashion segment is a positive sign, attributed to better operating leverage from marketing expenditures. The company’s management remains optimistic about sustaining growth across both beauty and fashion segments, particularly as the upcoming quarter is expected to benefit from events like Nykaaland and increased sales.

Divis Laboratories and Torrent Pharma: Mixed Ratings

Goldman Sachs has assigned a neutral rating to Divis Laboratories, with a target price of Rs 6,765. The company’s recent performance has exceeded expectations, with revenue and EBITDA growth of 16% and 24% year-on-year, respectively, driven by custom synthesis and a rebound in generics. The EBITDA margin of 32.7% reflects a favorable product mix and operational efficiencies. Divis Laboratories has reiterated its commitment to achieving double-digit growth in the coming years. Conversely, Jefferies has a buy rating for Torrent Pharma, with a target price of Rs 4,300. The company outperformed estimates in Q2FY26, primarily due to strong sales in the US and Brazil, although growth in Germany has been hindered by supply disruptions.

Bajaj Auto’s Steady Growth Amid Market Fluctuations

Nuvama has issued a hold rating on Bajaj Auto, slightly adjusting the target price from Rs 9,800 to Rs 9,700. The company reported a 14% increase in revenue and a 15% rise in EBITDA for Q2FY26, aligning with market expectations. Analysts forecast a compound annual growth rate of 7% in volume from FY25 to FY28. While domestic growth is anticipated to rise by 2%, exports are projected to increase by 13%. However, concerns linger over a potential decline in Bajaj Auto’s domestic two-wheeler market share, which is expected to drop from 12% in FY25 to 10% by FY28. Despite these challenges, the company’s export growth, particularly in Latin America and Asia, is expected to drive overall performance.

Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.

Follow Us on Twitter, Instagram, Facebook, & LinkedIn